Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03363997
Other study ID # GDN 005/16
Secondary ID
Status Completed
Phase Phase 1
First received November 27, 2017
Last updated November 30, 2017
Start date September 23, 2016
Est. completion date June 6, 2017

Study information

Verified date November 2017
Source Galeno Desenvolvimento de Pesquisas Clínicas
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial evaluated the pharmacokinetics and pharmacodynamics of estriol in healthy post-menopausal women after the application of one vaginal ring containing one of three different dosages of estriol (100 mg (Test 1), 300 mg (Test 2) or 600 mg (Test 3)) with continuous delivery (0.125, 0.250 or 0.500 mg/day) for 21 days. And also, characterized its safety and tolerability.


Description:

This phase I, single center, open-label, randomised (allocation to treatment), balanced, single dose trial was performed in a parallel-group design. The subjects were randomly assigned to one of the 3 possible treatments (single vaginal application of 1 vaginal ring containing 100, 300 or 600 mg estriol, with delivery rate of 0.125, 0.250 or 0.500 mg/day over 21 days.

Blood samples were collected at 0.5 h prior to drug application, 1, 2, 4, 6, 12, 24, 48, 96, 144, 216, 288, 360, 432 h after application; 5 min prior to removal, i.e., 21 d after application (study day 22), as well as 6, 12 and 24 h after removal to characterise pharmacokinetic parameters of estriol in plasma.

Serum concentrations of follicle stimulating hormone (FSH), luteinising hormone (LH) and sex hormone binding globulin (SHBG) and gynaecological parameters (cytology of vaginal smear, the maturation index and the vaginal pH) were evaluated as pharmacodynamic parameters.

The safety and tolerability was assessed by endometrial thickness and documentation of adverse events.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date June 6, 2017
Est. primary completion date December 15, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 45 Years and older
Eligibility Inclusion Criteria:

- Body-mass index (BMI) =18.5 kg/m² and = 30.0 kg/m²

- Postmenopausal state: FSH (plasma) = 40 IU/l, estradiol (serum) = 20 pg/ml last spontaneous menstruation at least 12 months ago

- Normal transvaginal endometrial scan (endometrial thickness < 5 mm)

- Good state of health

- Non-smoker or ex-smoker for at least 6 month

- Written informed consent, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the subjects participating in the clinical trial

Exclusion Criteria:

- Existing cardiac, hepatic and/or haematological diseases or pathological findings, which might interfere with the safety or tolerability and/or pharmacokinetics and/or pharmacodynamics of the active ingredient

- History of relevant central nervous system (CNS) and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders

- Known allergic reactions to the active ingredients used or to constituents of the pharmaceutical preparations

- Subjects with severe allergies or multiple drug allergies, unless it is judged as not relevant for the clinical trial by the investigator

- Positive anti-HIV-test (if positive to be verified by western blot), HBs-AG-test (if positive to be verified by test for HBc-IgM) or anti-HCV-test

- Presence or history of venous or arterial thrombosis (e.g. deep venous thrombosis, pulmonary embolism)

- Known, past or suspected breast cancer or increased familiar risk for development

- Known or suspected estrogen-dependent malignant tumours (e.g. endometrial or breast cancer)

- Undiagnosed genital bleeding

- Acute vaginal infection or other diseases prohibiting the placement of vaginal ring

- History of endometrial hyperplasia

- Migraine or frequent episodes of severe headache

- History of or current drug or alcohol dependence

- Subjects who are on a diet which could affect the pharmacokinetics of the active ingredient

- Regular intake of caffeine containing food or beverages of = 500 mg caffeine per day

- Blood donation or other blood loss of more than 400 ml within the last 3 months prior to individual enrolment of the subject

- Participation in a clinical trial during the last 6 months prior to individual enrolment of the subject

- Concomitant systemic therapy with antibiotics, which might interfere with enterohepatic recirculation (e.g. cephalosporines, neomycin, ampicillin or tetracyclines)

- Use of sex hormones within 6 months (oral, transdermal, vaginal) or 8 months (intramuscular administered depot preparations used once per month) or 12 months (intramuscular administered depot preparations used once per 3 months) before screening

- Use of systemic or topical medications or substances which oppose the study objectives or which might influence them within 8 weeks before screening examination

- Subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the clinical trial

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Estriol 0.125 mg/day
Application of one vaginal ring
Estriol 0.250 mg/day
Application of one vaginal ring
Estriol 0.500 mg/day
Application of one vaginal ring

Locations

Country Name City State
Brazil Galeno Desenvolvimento de Pesquisas Clinicas Ltda. - ME Campinas SP

Sponsors (2)

Lead Sponsor Collaborator
Galeno Desenvolvimento de Pesquisas Clínicas SocraTec R&D GmbH

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of estriol plasma levels Blood sampling for the determination of plasma levels of estriol in participants of each treatment group. 0-22 days
Secondary Maximum Plasma Concentration (Cmax) of estriol Determination of Cmax for estriol based on plasma concentrations of samples obtained. 0-22 days
Secondary Area Under the Curve (AUC) for estriol Calculation of the AUC for estriol based on plasma concentrations of samples obtained. 0-22 days
Secondary Characterisation of follicle stimulating hormone (FSH) Determination of serum concentrations of FSH under the three treatments 0-22 days
Secondary Characterisation of luteinising hormone (LH) Determination of serum concentrations of LH under the three treatments 0-22 days
Secondary Characterisation of sex hormone binding globulin (SHBG) Determination of serum concentrations of SHBG under the three treatments 0-22 days
Secondary Characterisation of cytology of vaginal smear Characterisation of cytology of vaginal smear (parabasal, intermediate and superficial cells) under the three treatments 0-22 days
Secondary Calculation of maturation index Calculation of maturation index under the three treatments 0-22 days
Secondary Determination of vaginal pH Determination of vaginal pH under the three treatments 0-22 days
Secondary Number of adverse events per participant Number of adverse events, in each treatment group, including clinically relevant alterations of vital signs and laboratory tests results. up to 22days after treatment
See also
  Status Clinical Trial Phase
Completed NCT04553029 - A Survey Evaluating Prevalence, Severity and Associated Factors in East Asian Women With Moderate-to-severe Menopause-related Vasomotor Symptoms (MR-VMS)
Completed NCT03672513 - Short-term Supplementation, Bone Turnover and Antioxidant Status in Menopause N/A
Terminated NCT03642119 - Validation of an Objective Instrument to Measure Hot Flashes During Menopause
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04210583 - RF and PEMF for Treatment of Vaginal Laxity and Mons Pubis and Labia for Improvement of Skin Laxity N/A
Completed NCT06057896 - Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
Completed NCT05617287 - An Exploratory Investigation of Dietary Supplementation and the Effect on Common Symptoms of Perimenopause and Menopause N/A
Recruiting NCT05180266 - Therapeutic Touch and Music in The Menopausal Period N/A
Recruiting NCT04043520 - Bioenergetic Effects of Aging and Menopause (BEAM) Phase 4
Completed NCT03663075 - Effect of Group Education and Individual Counselling on Mental Health and Quality of Life in 45-60 Year Old Women N/A
Not yet recruiting NCT04724135 - Assessment of Menopause Related Quality of Life Among Health Professionals in University Hospitals of UMC in Nur-Sultan
Not yet recruiting NCT04728126 - Menopausal Symptoms and Burnout: Comparison of Occupational Health Issue Among Health Professionals in UMC Hospitals
Completed NCT02274571 - Raising Insulin Sensitivity in Post Menopause Early Phase 1
Completed NCT02430987 - Low Sexual Desire and Metabolic Syndrome N/A
Completed NCT02253173 - Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women Phase 3
Completed NCT01757340 - Calorie Restriction With Leucine Supplementation N/A
Recruiting NCT01488903 - A Cohort Research of Genetic Susceptibility for Common Obesity in Women N/A
Terminated NCT01633814 - Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women N/A
Completed NCT00599456 - Investigation of the Usefulness of Omega 3 Vitamins in the Relief of Hot Flashes in Menopausal Women. N/A
Active, not recruiting NCT00152438 - Vasomotor Symptoms (VMS) Progesterone Study: Vasomotor Symptoms and Endothelial Function - Trial of Oral Micronized Progesterone Phase 2